Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME.
PMID: 34370182
Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09.

Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to...

Cite
Matossian MD, Chang T, Wright MK, et al. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2021;24(1):127-144doi: 10.1007/s12094-021-02677-8.
Matossian, M. D., Chang, T., Wright, M. K., Burks, H. E., Elliott, S., Sabol, R. A., Wathieu, H., Windsor, G. O., Alzoubi, M. S., King, C. T., Bursavich, J. B., Ham, A. M., Savoie, J. J., Nguyen, K., Baddoo, M., Flemington, E., Sirenko, O., Cromwell, E. F., Hebert, K. L., Lau, F., Izadpanah, R., Brown, H., Sinha, S., Zabaleta, J., Riker, A. I., Moroz, K., Miele, L., Zea, A. H., Ochoa, A., Bunnell, B. A., Collins-Burow, B. M., Martin, E. C., & Burow, M. E. (2022). In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 24(1), 127-144. https://doi.org/10.1007/s12094-021-02677-8
Matossian, M D, et al. "In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 24,1 (2022): 127-144. doi: https://doi.org/10.1007/s12094-021-02677-8
Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09. PMID: 34370182.
Copy Download .nbib Format: NLM
Disease Modeling with 3D Cell-Based Assays Using a Novel Flowchip System and High-Content Imaging.

SLAS technology

Cromwell EF, Leung M, Hammer M, Thai A, Rajendra R, Sirenko O.
PMID: 33783259
SLAS Technol. 2021 Jun;26(3):237-248. doi: 10.1177/24726303211000688. Epub 2021 Mar 30.

There is an increasing interest in using three-dimensional (3D) cell structures for modeling tumors, organs, and tissue to accelerate translational research. We describe here a novel automated organoid assay system (the Pu·MA System) combined with microfluidic-based flowchips that can...

Cite
Cromwell EF, Leung M, Hammer M, et al. Disease Modeling with 3D Cell-Based Assays Using a Novel Flowchip System and High-Content Imaging. SLAS Technol. 2021;26(3):237-248doi: 10.1177/24726303211000688.
Cromwell, E. F., Leung, M., Hammer, M., Thai, A., Rajendra, R., & Sirenko, O. (2021). Disease Modeling with 3D Cell-Based Assays Using a Novel Flowchip System and High-Content Imaging. SLAS technology, 26(3), 237-248. https://doi.org/10.1177/24726303211000688
Cromwell, Evan F, et al. "Disease Modeling with 3D Cell-Based Assays Using a Novel Flowchip System and High-Content Imaging." SLAS technology vol. 26,3 (2021): 237-248. doi: https://doi.org/10.1177/24726303211000688
Cromwell EF, Leung M, Hammer M, Thai A, Rajendra R, Sirenko O. Disease Modeling with 3D Cell-Based Assays Using a Novel Flowchip System and High-Content Imaging. SLAS Technol. 2021 Jun;26(3):237-248. doi: 10.1177/24726303211000688. Epub 2021 Mar 30. PMID: 33783259.
Copy Download .nbib Format: NLM
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME.
PMID: 34370182
Clin Transl Oncol. 2021 Aug 09; doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09.

Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to...

Cite
Matossian MD, Chang T, Wright MK, et al. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2021;doi: 10.1007/s12094-021-02677-8.
Matossian, M. D., Chang, T., Wright, M. K., Burks, H. E., Elliott, S., Sabol, R. A., Wathieu, H., Windsor, G. O., Alzoubi, M. S., King, C. T., Bursavich, J. B., Ham, A. M., Savoie, J. J., Nguyen, K., Baddoo, M., Flemington, E., Sirenko, O., Cromwell, E. F., Hebert, K. L., Lau, F., Izadpanah, R., Brown, H., Sinha, S., Zabaleta, J., Riker, A. I., Moroz, K., Miele, L., Zea, A. H., Ochoa, A., Bunnell, B. A., Collins-Burow, B. M., Martin, E. C., & Burow, M. E. (2021). In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, . https://doi.org/10.1007/s12094-021-02677-8
Matossian, M D, et al. "In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. (2021). doi: https://doi.org/10.1007/s12094-021-02677-8
Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2021 Aug 09; doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09. PMID: 34370182.
Copy Download .nbib Format: NLM
Chromatographic profiles and antimicrobial activity of the essential oils obtained from some species and cultivars of the .

Saudi journal of biological sciences

Shanaida M, Hudz N, Białoń M, Kryvtsowa M, Svydenko L, Filipska A, Paweł Wieczorek P.
PMID: 34759738
Saudi J Biol Sci. 2021 Nov;28(11):6145-6152. doi: 10.1016/j.sjbs.2021.06.068. Epub 2021 Jun 26.

The present study was focused on the chemical composition and antimicrobial activity of the essential oils (EsO) obtained from five

Cite
Shanaida M, Hudz N, Białoń M, et al. Chromatographic profiles and antimicrobial activity of the essential oils obtained from some species and cultivars of the . Saudi J Biol Sci. 2021;28(11):6145-6152doi: 10.1016/j.sjbs.2021.06.068.
Shanaida, M., Hudz, N., Białoń, M., Kryvtsowa, M., Svydenko, L., Filipska, A., & Paweł Wieczorek, P. (2021). Chromatographic profiles and antimicrobial activity of the essential oils obtained from some species and cultivars of the . Saudi journal of biological sciences, 28(11), 6145-6152. https://doi.org/10.1016/j.sjbs.2021.06.068
Shanaida, Mariia, et al. "Chromatographic profiles and antimicrobial activity of the essential oils obtained from some species and cultivars of the ." Saudi journal of biological sciences vol. 28,11 (2021): 6145-6152. doi: https://doi.org/10.1016/j.sjbs.2021.06.068
Shanaida M, Hudz N, Białoń M, Kryvtsowa M, Svydenko L, Filipska A, Paweł Wieczorek P. Chromatographic profiles and antimicrobial activity of the essential oils obtained from some species and cultivars of the . Saudi J Biol Sci. 2021 Nov;28(11):6145-6152. doi: 10.1016/j.sjbs.2021.06.068. Epub 2021 Jun 26. PMID: 34759738; PMCID: PMC8568706.
Copy Download .nbib Format: NLM
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME.
PMID: 34370182
Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09.

Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to...

Cite
Matossian MD, Chang T, Wright MK, et al. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2021;24(1):127-144doi: 10.1007/s12094-021-02677-8.
Matossian, M. D., Chang, T., Wright, M. K., Burks, H. E., Elliott, S., Sabol, R. A., Wathieu, H., Windsor, G. O., Alzoubi, M. S., King, C. T., Bursavich, J. B., Ham, A. M., Savoie, J. J., Nguyen, K., Baddoo, M., Flemington, E., Sirenko, O., Cromwell, E. F., Hebert, K. L., Lau, F., Izadpanah, R., Brown, H., Sinha, S., Zabaleta, J., Riker, A. I., Moroz, K., Miele, L., Zea, A. H., Ochoa, A., Bunnell, B. A., Collins-Burow, B. M., Martin, E. C., & Burow, M. E. (2022). In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 24(1), 127-144. https://doi.org/10.1007/s12094-021-02677-8
Matossian, M D, et al. "In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 24,1 (2022): 127-144. doi: https://doi.org/10.1007/s12094-021-02677-8
Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09. PMID: 34370182; PMCID: PMC8732292.
Copy Download .nbib Format: NLM
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME.
PMID: 34370182
Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09.

Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to...

Cite
Matossian MD, Chang T, Wright MK, et al. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2021;24(1):127-144doi: 10.1007/s12094-021-02677-8.
Matossian, M. D., Chang, T., Wright, M. K., Burks, H. E., Elliott, S., Sabol, R. A., Wathieu, H., Windsor, G. O., Alzoubi, M. S., King, C. T., Bursavich, J. B., Ham, A. M., Savoie, J. J., Nguyen, K., Baddoo, M., Flemington, E., Sirenko, O., Cromwell, E. F., Hebert, K. L., Lau, F., Izadpanah, R., Brown, H., Sinha, S., Zabaleta, J., Riker, A. I., Moroz, K., Miele, L., Zea, A. H., Ochoa, A., Bunnell, B. A., Collins-Burow, B. M., Martin, E. C., & Burow, M. E. (2022). In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 24(1), 127-144. https://doi.org/10.1007/s12094-021-02677-8
Matossian, M D, et al. "In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 24,1 (2022): 127-144. doi: https://doi.org/10.1007/s12094-021-02677-8
Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09. PMID: 34370182.
Copy Download .nbib Format: NLM
A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives.

Green chemistry : an international journal and green chemistry resource : GC

Grimm FA, Iwata Y, Sirenko O, Chappell GA, Wright FA, Reif DM, Braisted J, Gerhold DL, Yeakley JM, Shepard P, Seligmann B, Roy T, Boogaard PJ, Ketelslegers HB, Rohde AM, Rusyn I.
PMID: 28035192
Green Chem. 2016 Aug 21;18(16):4407-4419. doi: 10.1039/c6gc01147k. Epub 2016 May 16.

Comparative assessment of potential human health impacts is a critical step in evaluating both chemical alternatives and existing products on the market. Most alternatives assessments are conducted on a chemical-by-chemical basis and it is seldom acknowledged that humans are...

Cite
Grimm FA, Iwata Y, Sirenko O, et al. A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives. Green Chem. 2016;18(16):4407-4419doi: 10.1039/c6gc01147k.
Grimm, F. A., Iwata, Y., Sirenko, O., Chappell, G. A., Wright, F. A., Reif, D. M., Braisted, J., Gerhold, D. L., Yeakley, J. M., Shepard, P., Seligmann, B., Roy, T., Boogaard, P. J., Ketelslegers, H. B., Rohde, A. M., & Rusyn, I. (2016). A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives. Green chemistry : an international journal and green chemistry resource : GC, 18(16), 4407-4419. https://doi.org/10.1039/c6gc01147k
Grimm, Fabian A, et al. "A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives." Green chemistry : an international journal and green chemistry resource : GC vol. 18,16 (2016): 4407-4419. doi: https://doi.org/10.1039/c6gc01147k
Grimm FA, Iwata Y, Sirenko O, Chappell GA, Wright FA, Reif DM, Braisted J, Gerhold DL, Yeakley JM, Shepard P, Seligmann B, Roy T, Boogaard PJ, Ketelslegers HB, Rohde AM, Rusyn I. A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives. Green Chem. 2016 Aug 21;18(16):4407-4419. doi: 10.1039/c6gc01147k. Epub 2016 May 16. PMID: 28035192; PMCID: PMC5179981.
Copy Download .nbib Format: NLM
Time-and-frequency domains approach to data processing in multiwavelength optical scatterometry of dielectric gratings.

Journal of the Optical Society of America. A, Optics, image science, and vision

Granet G, Melezhik P, Sirenko K, Yashina N.
PMID: 23456118
J Opt Soc Am A Opt Image Sci Vis. 2013 Mar 01;30(3):427-36. doi: 10.1364/JOSAA.30.000427.

This paper focuses on scatterometry problems arising in lithography production of periodic gratings. Namely, the paper introduces a theoretical and numerical-modeling-oriented approach to scatterometry problems and discusses its capabilities. The approach allows for reliable detection of deviations in gratings'...

Cite
Granet G, Melezhik P, Sirenko K, et al. Time-and-frequency domains approach to data processing in multiwavelength optical scatterometry of dielectric gratings. J Opt Soc Am A Opt Image Sci Vis. 2013;30(3):427-36doi: 10.1364/JOSAA.30.000427.
Granet, G., Melezhik, P., Sirenko, K., & Yashina, N. (2013). Time-and-frequency domains approach to data processing in multiwavelength optical scatterometry of dielectric gratings. Journal of the Optical Society of America. A, Optics, image science, and vision, 30(3), 427-36. https://doi.org/10.1364/JOSAA.30.000427
Granet, Gérard, et al. "Time-and-frequency domains approach to data processing in multiwavelength optical scatterometry of dielectric gratings." Journal of the Optical Society of America. A, Optics, image science, and vision vol. 30,3 (2013): 427-36. doi: https://doi.org/10.1364/JOSAA.30.000427
Granet G, Melezhik P, Sirenko K, Yashina N. Time-and-frequency domains approach to data processing in multiwavelength optical scatterometry of dielectric gratings. J Opt Soc Am A Opt Image Sci Vis. 2013 Mar 01;30(3):427-36. doi: 10.1364/JOSAA.30.000427. PMID: 23456118.
Copy Download .nbib Format: NLM
Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

Journal of hypertension

Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, Scotti L, Zhang X, Guan TR, Zhang Y, Zhang X, Berge E, Redon J, Narkiewicz K, Dominiczak A, Nilsson P, Viigimaa M, Laurent S, Agabiti-Rosei E, Wu Z, Zhu D, Rodicio JL, Ruilope LM, Martell-Claros N, Pinto F, Schmieder RE, Burnier M, Banach M, Cifkova R, Farsang C, Konradi A, Lazareva I, Sirenko Y, Dorobantu M, Postadzhiyan A, Accetto R, Jelakovic B, Lovic D, Manolis AJ, Stylianou P, Dicker D, Wei G, Xu C, Xie H, Coca A, O'Brien J, Ford G.
PMID: 26780185
J Hypertens. 2016 Mar;34(3):393-6. doi: 10.1097/HJH.0000000000000853.

No abstract available.

Cite
Zanchetti A, Liu L, Mancia G, et al. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016;34(3):393-6doi: 10.1097/HJH.0000000000000853.
Zanchetti, A., Liu, L., Mancia, G., Parati, G., Grassi, G., Stramba-Badiale, M., Silani, V., Bilo, G., Corrao, G., Zambon, A., Scotti, L., Zhang, X., Guan, T. R., Zhang, Y., Zhang, X., Berge, E., Redon, J., Narkiewicz, K., Dominiczak, A., Nilsson, P., Viigimaa, M., Laurent, S., Agabiti-Rosei, E., Wu, Z., Zhu, D., Rodicio, J. L., Ruilope, L. M., Martell-Claros, N., Pinto, F., Schmieder, R. E., Burnier, M., Banach, M., Cifkova, R., Farsang, C., Konradi, A., Lazareva, I., Sirenko, Y., Dorobantu, M., Postadzhiyan, A., Accetto, R., Jelakovic, B., Lovic, D., Manolis, A. J., Stylianou, P., Dicker, D., Wei, G., Xu, C., Xie, H., Coca, A., O'Brien, J., Ford, G. (2016). Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. Journal of hypertension, 34(3), 393-6. https://doi.org/10.1097/HJH.0000000000000853
Zanchetti, Alberto, et al. "Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke." Journal of hypertension vol. 34,3 (2016): 393-6. doi: https://doi.org/10.1097/HJH.0000000000000853
Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, Scotti L, Zhang X, Guan TR, Zhang Y, Zhang X, Berge E, Redon J, Narkiewicz K, Dominiczak A, Nilsson P, Viigimaa M, Laurent S, Agabiti-Rosei E, Wu Z, Zhu D, Rodicio JL, Ruilope LM, Martell-Claros N, Pinto F, Schmieder RE, Burnier M, Banach M, Cifkova R, Farsang C, Konradi A, Lazareva I, Sirenko Y, Dorobantu M, Postadzhiyan A, Accetto R, Jelakovic B, Lovic D, Manolis AJ, Stylianou P, Dicker D, Wei G, Xu C, Xie H, Coca A, O'Brien J, Ford G. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016 Mar;34(3):393-6. doi: 10.1097/HJH.0000000000000853. PMID: 26780185.
Copy Download .nbib Format: NLM
Efficient discontinuous Galerkin scheme for analyzing nanostructured photoconductive devices.

Optics express

Chen L, Sirenko K, Li P, Bagci H.
PMID: 33985036
Opt Express. 2021 Apr 26;29(9):12903-12917. doi: 10.1364/OE.422619.

Incorporation of plasmonic nanostructures in the design of photoconductive devices (PCDs) has significantly improved their optical-to-terahertz conversion efficiency. However, this improvement comes at the cost of increased complexity for the design and simulation of these devices. Indeed, accurate and...

Cite
Chen L, Sirenko K, Li P, et al. Efficient discontinuous Galerkin scheme for analyzing nanostructured photoconductive devices. Opt Express. 2021;29(9):12903-12917doi: 10.1364/OE.422619.
Chen, L., Sirenko, K., Li, P., & Bagci, H. (2021). Efficient discontinuous Galerkin scheme for analyzing nanostructured photoconductive devices. Optics express, 29(9), 12903-12917. https://doi.org/10.1364/OE.422619
Chen, Liang, et al. "Efficient discontinuous Galerkin scheme for analyzing nanostructured photoconductive devices." Optics express vol. 29,9 (2021): 12903-12917. doi: https://doi.org/10.1364/OE.422619
Chen L, Sirenko K, Li P, Bagci H. Efficient discontinuous Galerkin scheme for analyzing nanostructured photoconductive devices. Opt Express. 2021 Apr 26;29(9):12903-12917. doi: 10.1364/OE.422619. PMID: 33985036.
Copy Download .nbib Format: NLM
Modifying effects of .

Drug metabolism and personalized therapy

Fishchuk L, Rossokha Z, Pokhylko V, Cherniavska Y, Tsvirenko S, Kovtun S, Medvedieva N, Vershyhora V, Gorovenko N.
PMID: 34860474
Drug Metab Pers Ther. 2021 Dec 06; doi: 10.1515/dmpt-2021-0127. Epub 2021 Dec 06.

OBJECTIVES: COVID-19 continues to range around the world and set morbidity and mortality antirecords. Determining the role of genetic factors in the development of COVID-19 may contribute to the understanding of the pathogenetic mechanisms that lead to the development...

Cite
Fishchuk L, Rossokha Z, Pokhylko V, et al. Modifying effects of . Drug Metab Pers Ther. 2021;doi: 10.1515/dmpt-2021-0127.
Fishchuk, L., Rossokha, Z., Pokhylko, V., Cherniavska, Y., Tsvirenko, S., Kovtun, S., Medvedieva, N., Vershyhora, V., & Gorovenko, N. (2021). Modifying effects of . Drug metabolism and personalized therapy, . https://doi.org/10.1515/dmpt-2021-0127
Fishchuk, Liliia, et al. "Modifying effects of ." Drug metabolism and personalized therapy vol. (2021). doi: https://doi.org/10.1515/dmpt-2021-0127
Fishchuk L, Rossokha Z, Pokhylko V, Cherniavska Y, Tsvirenko S, Kovtun S, Medvedieva N, Vershyhora V, Gorovenko N. Modifying effects of . Drug Metab Pers Ther. 2021 Dec 06; doi: 10.1515/dmpt-2021-0127. Epub 2021 Dec 06. PMID: 34860474.
Copy Download .nbib Format: NLM
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME.
PMID: 34370182
Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09.

Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to...

Cite
Matossian MD, Chang T, Wright MK, et al. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2021;24(1):127-144doi: 10.1007/s12094-021-02677-8.
Matossian, M. D., Chang, T., Wright, M. K., Burks, H. E., Elliott, S., Sabol, R. A., Wathieu, H., Windsor, G. O., Alzoubi, M. S., King, C. T., Bursavich, J. B., Ham, A. M., Savoie, J. J., Nguyen, K., Baddoo, M., Flemington, E., Sirenko, O., Cromwell, E. F., Hebert, K. L., Lau, F., Izadpanah, R., Brown, H., Sinha, S., Zabaleta, J., Riker, A. I., Moroz, K., Miele, L., Zea, A. H., Ochoa, A., Bunnell, B. A., Collins-Burow, B. M., Martin, E. C., & Burow, M. E. (2022). In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 24(1), 127-144. https://doi.org/10.1007/s12094-021-02677-8
Matossian, M D, et al. "In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 24,1 (2022): 127-144. doi: https://doi.org/10.1007/s12094-021-02677-8
Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 09. PMID: 34370182; PMCID: PMC8732292.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries